GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sensorion ALSEN.PA · EUR

Health Care · Euronext Paris · 🇫🇷 France

Compare

8.66

-2.04%

Close of 9 Nov 2026, in EUR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Sensorion

Its shares trade on Euronext Paris under the ticker ALSEN.PA. It has been listed since 21 April 2015. In the fiscal year to 31 December 2024, it reported revenue of €6.7m and a net loss of €26.0m. At that date it held total assets of €89.3m and shareholders' equity of €72.1m.

Sensorion SAS is a biopharmaceutical company, which engages in the development of therapies to treat and prevent diseases of the inner ear such as deafness, vertigo and tinnitus. The company is headquartered in Montpellier, Occitanie. The company went IPO on 2015-04-21. The firm is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The firm develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
21 Apr 2015
Employees
18

Leadership

Pay as last reported

  • Mr. Amit MunshiIndependent Chairman of the Board, since 2025
  • Mrs. Nawal OuzrenChief Executive Officer, Director
  • Ms. Laurene DanonChief Financial Officer
  • Mr. Bernd SchmidtChief Technical Officer
  • Ms. Geraldine HonnetChief Medical Officer
  • Mr. Khalil BarrageDirector, since 2019
  • Ms. Natalie BernerDirector - Representative of Redmile Group
  • Mr. Julien MiaraDirector - Representative of Invus
  • Mr. Cedric MoreauDirector - Representing Sofinnova Partners
  • Dr. Federico MingozziNon-Executive Director
  • Dr. Eric de La FortelleIndependent Director - Represent of Health Opportunities, since 2019€33,000
  • Mr. John FureyIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Sensorion SA possesses several strengths that contribute to its competitiveness and market position. These strengths include:

Weaknesses

  • Despite its strengths, Sensorion SA also faces certain weaknesses and areas of improvement, such as:

Opportunities

  • Sensorion SA can explore various opportunities to grow and expand its business, including:

Threats

  • While Sensorion SA strives for success, it faces certain threats and challenges that can hinder its progress, including:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.